Generic name: diroximel fumarate 231mg
Dosage form: capsule
Medically reviewed by Drugs.com. Last updated on Nov 12, 2019.
Blood Tests Prior to Initiation of VUMERITY
Obtain the following prior to treatment with VUMERITY:
The starting dosage for VUMERITY is 231 mg twice a day orally. After 7 days, the dosage should be increased to the maintenance dosage of 462 mg (administered as two 231 mg capsules) twice a day orally. Temporary dosage reductions to 231 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 462 mg twice a day should be resumed. Discontinuation of VUMERITY should be considered for patients unable to tolerate return to the maintenance dosage. Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to VUMERITY dosing may reduce the incidence or severity of flushing [see Clinical Pharmacology (12.3)].
Swallow VUMERITY capsules whole and intact. Do not crush or chew, or sprinkle the capsule contents on food.
If taken with food, avoid a high-fat, high-calorie meal/snack; the meal/snack should contain no more than 700 calories and no more than 30 g fat [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)].
Avoid co-administration of VUMERITY with alcohol [see Clinical Pharmacology (12.3)].
Blood Tests to Assess Safety After Initiation of VUMERITY
Obtain a complete blood cell count (CBC), including lymphocyte count, 6 months after initiation of VUMERITY and then every 6 to 12 months thereafter, as clinically indicated [see Warnings and Precautions (5.3)].
Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels during treatment with VUMERITY, as clinically indicated [see Warnings and Precautions (5.4)].
More about Vumerity (diroximel fumarate)
- Side Effects
- During Pregnancy
- Imprints, Shape & Color Data
- Drug Interactions
- En Español
- Drug class: selective immunosuppressants
- FDA Approval History